title: The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera.
abstract: Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events. Current guidelines advise maintaining hematocrit (HCT) level below 45% in males and 42% in females. Such targets lean on pathophysiological reasoning, while evidence from ECLAP and PVSG-01, the two largest prospective studies in this disease, suggests no difference in the rate of thrombosis in patients maintained at different HCT values below 50%-52%. Cytoreductive therapy in PV (CYTO-PV) is a multicenter, randomized, and controlled trial assess the benefit/risk profile of cytoreductive therapy with phlebotomy or HU aimed at maintaining HCT < 45% versus maintaining HCT in the range 45%-50%. CYTO-PV is being conducted in the framework of the Gruppo Italiano Malattie Ematologiche nell'Adulto (GIMEMA) and is funded by the Italian Drug Agency (AIFA). It is an independent trial with broad recruitment criteria to mimic clinical practice. We describe here the study and its advancement status. Conclusions. Clinical research in rare disease can be carried out with limited funds, provided a research hypothesis is felt as clinically relevant by a scientific community willing to share knowledge on the outcome of clinical practice, thus producing scientific results useful to improve treatment and prognosis of patients.
authors.affiliation: CYTO-PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy.
authors.forename: Roberto
authors.initials: R
authors.lastname: Marchioli
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.forename: Arianna
authors.initials: A
authors.lastname: Masciulli
authors.forename: Maria Rosaria
authors.initials: MR
authors.lastname: Mennitto
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
references.citation: Blood. 2007 Jun 15;109(12):5104-11
references.pmid: 17264301
references.citation: Blood. 2002 Dec 15;100(13):4272-90
references.pmid: 12393615
references.citation: Lancet. 1978 Dec 9;2(8102):1219-22
references.pmid: 82733
references.citation: Thromb Haemost. 2006 Nov;96(5):562-7
references.pmid: 17080211
references.citation: Semin Hematol. 1986 Apr;23(2):132-43
references.pmid: 3704665
references.citation: Br J Haematol. 2007 Jan;136(2):249-59
references.pmid: 17156406
references.citation: Blood. 2008 Jul 15;112(2):231-9
references.pmid: 18401028
references.citation: Lancet. 1977 Nov 5;2(8045):941-3
references.pmid: 72286
references.citation: Blood. 2009 Jul 23;114(4):759-63
references.pmid: 19372254
references.citation: Cancer J. 2007 Nov-Dec;13(6):372-6
references.pmid: 18032974
references.citation: Leukemia. 2007 Sep;21(9):1952-9
references.pmid: 17625606
references.citation: Cancer. 2006 Feb 1;106(3):631-5
references.pmid: 16369984
references.citation: Haematologica. 2008 Mar;93(3):331-5
references.pmid: 18310537
references.citation: Thromb Haemost. 1997 Jul;78(1):617-21
references.pmid: 9198226
references.citation: Br J Haematol. 2005 Jul;130(2):174-95
references.pmid: 16029446
references.citation: J Thromb Haemost. 2008 Oct;6(10):1720-5
references.pmid: 18680535
references.citation: Semin Hematol. 2005 Oct;42(4):206-20
references.pmid: 16210034
references.citation: Thromb Haemost. 2008 Aug;100(2):240-5
references.pmid: 18690343
references.citation: Blood. 2002 Feb 15;99(4):1144-9
references.pmid: 11830459
references.citation: Thromb Haemost. 2006 Nov;96(5):553-61
references.pmid: 17080210
references.citation: Leukemia. 2008 Nov;22(11):2020-8
references.pmid: 18800144
references.citation: Leuk Lymphoma. 1996 Sep;22 Suppl 1:121-7
references.pmid: 8951782